Core Insights - Nutex Health Inc. is preparing for its quarterly earnings announcement on September 18, 2025, with an expected EPS of -$5.43 and projected revenue of approximately $210.89 million [1][6] Financial Performance - The company is currently facing a class-action lawsuit alleging deceptive billing practices, which may impact its financial outlook [2][6] - Despite the legal challenges, Nutex's price-to-sales ratio is around 0.80, indicating it may be undervalued [3][6] - The enterprise value to sales ratio is approximately 1.21, and the enterprise value to operating cash flow ratio is about 10.64, providing insights into the company's valuation and cash flow generation capabilities [4] - Nutex's debt-to-equity ratio is reported at 1.73, suggesting a higher level of debt relative to equity, while the current ratio is approximately 2.27, indicating a strong capacity to cover short-term liabilities [5]

Core Viewpoint - Nutex Health Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 8, 2024, and August 14, 2025, impacting investors adversely [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Nutex Health Inc. made false statements and concealed information regarding its third-party vendor HaloMD, which allegedly engaged in fraudulent activities to defraud insurance companies [2]. - It is alleged that revenues from Nutex's engagement with HaloMD were unsustainable due to the fraudulent nature of the conduct [2]. - The company reportedly overstated its remediation efforts regarding material weaknesses in its internal controls over financial reporting, leading to improper accounting of stock-based compensation obligations [2]. - As a result of these issues, Nutex Health Inc. faced increased risks of failing to file financial reports with the SEC in a timely manner, which overstated its business and financial prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, indicating a no-cost participation model [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years, indicating its expertise in handling complex securities cases [4].

Accessibility StatementSkip Navigation https://zlk.com/pslra-1/nutex-health-inc-lawsuit-submission-form?prid=167310&wire=4 NUTX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) HaloMD, a third-party IDR vendor, was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii ...

NEW YORK , Sept. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nutex Health Inc. (NASDAQ: NUTX). ...

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][9] Group 1: Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant losses [1][2] - Allegations include a systematic effort to exploit the insurance arbitration process, submitting thousands of questionable claims to extract outsized reimbursements [2][3] - The lawsuit asserts that Nutex's revenue model is built on unstable foundations, misleading investors about the company's true financial health [2][9] Group 2: Market Reaction - Following the release of a report by Blue Orca Capital, Nutex shares dropped over 10%, indicating investor unease regarding the allegations [4] - After announcing a delay in its Form 10-Q due to "non-cash accounting adjustments," Nutex shares plunged 16.39%, closing at $92.91 [6] Group 3: Financial Reporting Issues - The lawsuit accuses Nutex of misrepresenting its progress in addressing internal control deficiencies, particularly in misclassifying stock-based compensation obligations [5] - On August 21, Nutex disclosed that its Audit Committee determined certain prior financial statements required restatement due to incorrect classification of obligations [7] Group 4: Ongoing Investigations - Hagens Berman is investigating the claims against Nutex, focusing on whether the company's business model relied on questionable arbitration tactics and misleading financial reporting [10]

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Nutex Health Inc. investors who were adversely affected by alleged securities fraud between August 8, 2024 and August 14, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/nutex-health-inc-lawsuit-submission-form?prid=166637&wire=4 Accessibility StatementSkip Navigation NEW YORK, Sept. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Nutex Health Inc. ("N ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Nutex Health Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit set for October 21, 2025 [3][5]. Group 1: Allegations Against Nutex - The complaint alleges that Nutex and its executives made false and misleading statements, failing to disclose a coordinated scheme to defraud insurance companies through HaloMD [5]. - It is claimed that revenues from HaloMD's engagement were unsustainable due to fraudulent conduct, and Nutex overstated its ability to remediate weaknesses in its internal controls over financial reporting [5]. - Nutex is accused of improperly calculating stock-based compensation obligations, which increased the risk of failing to file timely financial reports with the SEC [5]. Group 2: Market Reaction - Following the release of a short report by Blue Orca Capital, Nutex's stock price fell by $11.18 per share, or 10.05%, closing at $100.01 on July 22, 2025 [6][7]. - After Nutex announced a delay in filing its Form 10-Q due to accounting adjustments, its stock price dropped further by $18.22 per share, or 16.39%, closing at $92.91 on August 15, 2025 [8]. Group 3: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff [9]. - Faruqi & Faruqi encourages individuals with information regarding Nutex's conduct to come forward, including whistleblowers and former employees [10].

Core Viewpoint - Nutex Health Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 8, 2024, and August 14, 2025, impacting investors adversely [1][2]. Group 1: Allegations and Claims - The lawsuit claims that Nutex Health Inc. made false statements and concealed information regarding its third-party vendor HaloMD, which allegedly engaged in fraudulent activities to defraud insurance companies [2]. - It is alleged that revenues from Nutex's engagement with HaloMD were unsustainable due to the fraudulent conduct [2]. - The company purportedly overstated its remediation efforts regarding material weaknesses in its internal controls over financial reporting [2]. - Nutex is accused of improperly accounting for stock-based compensation obligations, treating them as equity instead of liabilities [2]. - The allegations suggest that these issues increased the risk of Nutex failing to file certain financial reports with the SEC in a timely manner [2]. - Consequently, the lawsuit asserts that Nutex's business and financial prospects were overstated, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, highlighting its expertise in complex securities litigation [4].

Core Viewpoint - Nutex Health Inc. is facing allegations of issuing materially false and misleading statements during the class period from August 8, 2024, to August 14, 2025, related to its financial reporting and business practices [1]. Group 1: Allegations Against Nutex Health Inc. - The complaint alleges that Nutex's third-party vendor, HaloMD, engaged in fraudulent activities to defraud insurance companies, leading to unsustainable revenue [1]. - Nutex is accused of overstating its remediation efforts regarding material weaknesses in its internal controls over financial reporting [1]. - The company improperly classified stock-based compensation obligations as equity instead of liabilities, increasing the risk of delayed financial report filings with the SEC [1]. Group 2: Class Action Details - Shareholders who purchased shares of Nutex during the specified class period are encouraged to register for the class action, with a deadline of October 21, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].

Core Viewpoint - Nutex Health Inc. is facing significant legal challenges while preparing to release its quarterly earnings, with mixed financial metrics indicating both potential and risk for investors [1][2][6]. Financial Performance - The company is expected to report an earnings per share (EPS) of -$5.43 and projected revenue of approximately $210.89 million for the upcoming quarter [1][6]. - Nutex has a price-to-earnings (P/E) ratio of approximately 6.84, suggesting a low market valuation of its earnings [4][6]. - The price-to-sales ratio stands at about 0.74, indicating a relatively low valuation compared to its sales [4][6]. - The enterprise value to sales ratio is 1.15, which is slightly higher than its total sales [4]. Legal Challenges - The company is currently involved in a class-action lawsuit for alleged securities law violations, with a deadline of October 21, 2025, for investors to file as lead plaintiffs [2][6]. - Allegations include fraudulent activities and misleading investors about the company's financial health, particularly through deceptive billing strategies linked to its vendor HaloMD [2][3]. Financial Health Indicators - Nutex's earnings yield is reported at 14.63%, indicating a potential return on investment for shareholders [5][6]. - The debt-to-equity ratio is 1.73, reflecting significant debt usage compared to equity [5]. - A current ratio of 2.27 suggests a strong ability to cover short-term liabilities with short-term assets, providing some reassurance to investors despite ongoing legal issues [5].